Kuwait’s Minister of Health, Dr. Ahmad Al-Awadhi, has approved Ministerial Resolution No. 93 of 2025, which sets the official prices for 69 new medicines and pharmaceutical products available in private sector pharmacies. The initiative is part of the Health Ministry’s broader plan to improve healthcare accessibility while ensuring quality and economic sustainability.
In a press release, the Ministry stated that the resolution is based on recommendations from the Drug Pricing Committee and supports ongoing efforts to monitor pharmaceutical pricing and reduce the financial burden on patients without compromising treatment quality.
The new pricing list includes a broad spectrum of medications, such as treatments for cancer (including leukemia), diabetes, high blood pressure, cholesterol, blood thinners, antidepressants, antiepileptics, antibiotics, antifungals, antivirals, asthma, osteoporosis, thyroid issues, dermatological conditions, Alzheimer’s, dementia, obesity, and migraines.
This resolution complements Ministerial Resolution No. 74 of 2023 and builds on the Ministry’s previous actions, including a 30% price reduction for tirzepatide injections (used for diabetes and weight loss) announced last week. In recent months, Kuwait also approved the prices of 146 medicines in March 2025, reduced prices of over 200 medicines in July 2024, and approved pricing for 228 pharmaceutical products in May 2024.
The Ministry reaffirmed its commitment to maintaining a balanced, affordable, and sustainable healthcare system for all citizens and residents.
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Velit omnis animi et iure laudantium vitae, praesentium optio, sapiente distinctio illo?